Home > AnPac Bio-Medical Science Co. Ltd. ANPC > Page 4

Tag: AnPac Bio-Medical Science Co. Ltd. ANPC

FridayAug 06, 2021 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021

Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1 The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings The global cancer diagnostics market size is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening, detection, and cancer treatment, announced that it experienced strong growth in test volume in the…

Continue Reading

ThursdayAug 05, 2021 1:56 pm

QualityStocksNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Enters Strategic Collaboration to Explore Innovative Products and Medical Solutions

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced its entry into a cooperation agreement with Roche Pharmaceuticals China (“Roche”) to leverage both parties’ advantages and sources to explore novel health care and medical solutions and collaboration models in early cancer screening, early diagnosis and early treatment. According to the update, AnPac Bio and Roche will jointly explore personalized product lines and solutions and will target the general population for early cancer screening, hospital diagnosis, and precision medicine through therapy selection testing. The synergistic collaboration plans to form a competitive package of…

Continue Reading

WednesdayAug 04, 2021 2:17 pm

AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening

Summary After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. According to US marketing research firm Frost-Sullivan, AnPac Bio ranked top three globally in terms of clinical and commercial test sample numbers in the space of new cancer detection technologies in 2019. In the next five years, AnPac Bio strives to become a global leader…

Continue Reading

MondayAug 02, 2021 9:30 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection The global cancer diagnostics market is expected to reach $249.6 billion by 2026 AnPac Bio-Medical Science…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered

512.354.7000

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .